Parkinson's: Over 8 Hours of Activity a Week, Slower Decline

Jeff's Daily Pick. People with Parkinson's who moved more than 8 hours a week saw their thinking scores barely budge year to year. Those under 4 hours lost 68 times more.

In the United States, researchers at the University of Cincinnati followed 294 people with mild to moderate Parkinson's disease for up to seven years. Their study, published on October 7, 2026 in Neurology, found that more physical activity went with slower declines in both thinking and movement. The strongest associations were in people reporting more than eight hours of activity a week.

Who and how

Participants had a mean age of 66.4 and 33.0% were women. They reported weekly hours of activity at work, at home and in hobbies or recreation, including brisk walking, household chores such as vacuuming or mowing, and heavier tasks. Researchers split them into thirds by total activity time: up to four hours a week, four to eight hours, and more than eight. Thinking was tested yearly with the 30 point Montreal Cognitive Assessment (MoCA) for up to five years, and movement with the MDS UPDRS part III for up to seven.

The results

The yearly MoCA change was minus 0.478 points in the low group, minus 0.090 in the middle and minus 0.007 in the high group. On the movement scale, where higher means worse, the low group gained 0.143 points a year, while the middle and high groups improved by 0.225 and 0.783. Compared with the lowest third, the highest showed slower cognitive decline (beta 0.470; 95% CI 0.203 to 0.737; p < 0.001) and slower motor progression (beta minus 0.926; 95% CI minus 1.835 to minus 0.017; p = 0.048). Vigorous activity time was associated too, but the authors concluded that total duration mattered more than intensity.

The motor result is borderline, with a confidence interval that nearly touches zero; the cognitive one is clearer. The direction matches randomized trials showing short term motor benefits from exercise in Parkinson's. A trial assigning people to more weekly activity would settle what this cohort cannot. Our piece on a Parkinson's drug trial covers the treatment side.